Vascular Health and Risk Management (Sep 2021)
Is There a Difference in the Clinical Efficacy of Diosmin and Micronized Purified Flavonoid Fraction for the Treatment of Chronic Venous Disorders? Review of Available Evidence
Abstract
Michèle Cazaubon,1 Jean-Patrick Benigni,2 Marcio Steinbruch,3 Violaine Jabbour,4 Christelle Gouhier-Kodas4 1Private Vascular Specialist, Paris, France; 2Pedagogical Support Office, Faculty of Medicine Pitié-Salpétrière, Sorbonne University, Paris, France; 3Hospital Albert Einstein, São Paulo, Brazil; 4Laboratoire Innotech International, Arcueil, FranceCorrespondence: Christelle Gouhier-Kodas Email [email protected]: Flavonoids are oral venoactive drugs frequently prescribed to relieve the symptoms of chronic venous disorders (CVD). Among venoactive drugs, diosmin is a naturally occurring flavonoid glycoside that can be isolated from various plant sources; it can also be obtained after conversion of hesperidin extracted from citrus rinds. Micronized purified flavonoid fraction (MPFF) is a preparation that contains mainly diosmin and a small fraction of hesperidin. We performed a state-of-the-art literature review to collect and analyze well-conducted randomized clinical studies comparing diosmin – also called non-micronized or hemisynthetic diosmin – 600 mg a day and MPFF, 1000 mg a day. Three clinical studies met the criteria and were included for this literature review. These clinical studies showed a significant decrease of CVD symptom intensity (up to approximately 50%) and global patient satisfaction after one-to-six-month treatment with diosmin or MPFF, without statistical differences between these two forms of diosmin. Both treatments were well tolerated with few mild adverse drug reactions reported. Overall, based on this literature review, there is no clinical benefit to increase the dose of diosmin beyond 600 mg per day, to use the micronized form, or to add hesperidin, since clinical efficacy on venous symptomatology is achieved with 600 mg per day of pure non-micronized diosmin. This challenges the status of diosmin – 600 mg a day – in guidelines for the management of CVD, which is currently categorized 2C (weak recommendations for use and poor quality of evidence), while the most widely used and assessed preparation MPFF is rated 1B (strong recommendation for use and moderate quality of evidence).Keywords: chronic venous disorders, venoactive drugs, flavonoids, randomized clinical trials, literature review
